Role of vitamin D metabolism in cutaneous tumour formation and progression

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 1, 2013, Pages 2-10

  Nemazannikova, Natalie ^a   Antonas, Kiriakos ^a   Dass, Crispin R ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

dermal fibroblast; skin cancer; vitamin D

Indexed keywords

CALCIFEDIOL; CALCITRIOL; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

BASAL CELL CARCINOMA; BIOSYNTHESIS; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CELL DIFFERENTIATION; CELL GROWTH; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; METABOLITE; MOLECULAR PATHOLOGY; NONHUMAN; PRECANCER; PROTEIN EXPRESSION; RADIATION EXPOSURE; REGULATORY MECHANISM; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN METASTASIS; SKIN PROTECTION; SKIN SURGERY; SUN EXPOSURE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; STROMAL CELLS; SUNLIGHT; VITAMIN D;

EID: 84870873592     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01527.x     Document Type: Review

References (95)

1. Dowdy JC, et al,. Holick's rule and vitamin D from sunlight. J Steroid Biochem Mol Biol. 2012; 121: 328-330.
2. Padgett JK, Hendrix JJD,. Cutaneous malignancies and their management. Otolaryngol Clin North Am 2001; 34: 523-553.
3. Holick MF,. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006; 92: 49-59.
4. Ahmed AH, et al,. Non-melanoma skin cancers. Drug Discov Today 2008; 5: e55-e62.
5. Arora A, Attwood J,. Common skin cancers and their precursors. Surg Clin North Am 2009; 89: 703-712.
6. Haug RH,. Epidemiology of nonmelanoma skin cancer: Strom SS, Yamamura Y. Clin Plast Surg 24:627, 1997. J Oral Maxillofac Surg 1998; 56: 1006-1006.
7. Schreiber MM, et al,. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol 1990; 23 (6, Part 1) 1114-1118.
8. Chen TC, Holick MF,. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003; 14: 423-430.
9. Li H, et al,. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007; 4: 0562-0571.
10. Garland CF, et al,. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007; 103: 708-711.
11. Grant WB,. Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 2010; 101: 130-136.
12. Pérez-López FR, et al,. Review article: vitamin D acquisition and breast cancer risk. Reprod Sci 2009; 16: 7-19.
13. Spina CS, et al,. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol Biol 2007; 103: 757-762.
14. Gorham ED, et al,. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005; 97: 179-194.
15. Krishnan AV, et al,. The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 2010; 39: 401-418.
16. Otani T, et al,. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J Cancer 2007; 97: 446-451.
17. Holick MF,. Sunlight 'D'ilemma: risk of skin cancer or bone disease and muscle weakness. Lancet 2001; 357: 4-6.
18. Reichrath J., The challenge resulting from positive and negative effects of sunlight: how much solar UV exposure is appropriate to balance between risks of vitamin D deficiency and skin cancer? Prog Biophys Mol Biol 2006; 92: 9-16.
19. Moan J, et al,. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. PNAS 2007; 105: 668-673.
20. Gorham ED, et al,. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007; 32: 210-216.
21. Chung I, et al,. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009; 69: 967-975.
22. Deeb KK, et al,. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700.
23. van Leeuwen JPTM, et al,. Vitamin D: cancer and differentiation, In:, Feldman D, et al., eds. Vitamin D (2). Burlington: Academic Press, 2005: 1571-1597.
24. Bikle DD, et al,. Calcium- and vitamin d-regulated keratinocyte differentiation. Mol Cell Endocrinol 2001; 177: 161-171.
25. De Haes P, et al,. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B 2005; 78: 141-148.
26. Wong G, et al,. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Biol 2004; 89-90: 567-570.
27. Nemanic MK, et al,. In vitro synthesis of vitamin D-3 by cultured human keratinocytes and fibroblasts: action spectrum and effect of AY-9944. Biochim Biophys Acta 1985; 841: 267-277.
28. Michael Sebag S, et al,. Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. J Biol Chem 1992; 267: 12162-12167.
29. Godar DE, et al,. Increased UVA exposures and decreased cutaneous Vitamin D3 levels may be responsible for the increasing incidence of melanoma. Med Hypotheses 2009; 72: 434-443.
30. Shih M-K, Hu M-L,. UVA-induced oxidative damage to rat liver nuclei: reduction of iron ions and the relationship between lipid peroxidation and DNA damage. Mutat Res 1999; 438: 125-132.
31. Bachelor MA, Bowden GT,. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin Cancer Biol 2004; 14: 131-138.
32. Basu-Modak S, et al,. Epicatechin and its methylated metabolite attenuate UVA-induced oxidative damage to human skin fibroblasts. Free Radic Biol Med 2003; 35: 910-921.
33. Payette MJ, et al,. Nutrition and nonmelanoma skin cancers. Clin Dermatol 2010; 28: 650-662.
34. Holick MF, Benjamin C,. VITAMIN D | physiology, dietary sources and requirements. In:, Caballero B, ed. Encyclopedia of Human Nutrition. Oxford: Elsevier, 2005: 368-377.
35. Black HS,. Influence of dietary factors on actinically-induced skin cancer. Mutat Res 1998; 422: 185-190.
36. Lehmann B,. Role of the vitamin D3 pathway in healthy and diseased skin-facts, contradictions and hypotheses. Exp Dermatol 2009; 18: 97-108.
37. Bikle DD,. Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. J Invest Dermatol 2008; 128: 2357-2361.
38. Baeke F, et al,. Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Aspects Med 2008; 29: 376-387.
39. Nürnberg JRAB,. Cutaneous vitamin D synthesis versus skin cancer development. Dermatoendocrinology 2009; 1: 253-261.
40. Vinceti M, et al,. Inverse association between dietary vitamin D and risk of cutaneous melanoma in a northern Italy population. Nutr Cancer 2011; 1: 1-8.
41. Giovannucci E, et al,. Epidemiology of cancer risk: vitamin D and calcium. In:, Feldman D, et al., eds. Vitamin D (2). Burlington: Academic Press, 2005: 1617-1634.
42. Dixon KM, et al,. In vivo relevance for photoprotection by the vitamin D rapid response pathway. J Steroid Biochem Mol Biol 2007; 103: 451-456.
43. Bouillon R, et al,. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006; 102: 156-162.
44. 3 metabolism in human skin. J Invest Dermatol 1997; 108: 78-82.
45. Banerjee P, Chatterjee M,. Antiproliferative role of vitamin D and its analogs-a brief overview. Mol Cell Biochem 2003; 253: 247-254.
46. Mason RS, et al,. Photoprotection by 1[alpha],25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J Steroid Biochem Mol Biol 2010; 121: 164-168.
47. Bikle DD, et al,. Vitamin D and skin cancer: a problem in gene regulation. J Steroid Biochem Mol Biol 2005; 97: 83-91.
48. El-Deiry WS,. Targeting mutant p53 shows promise for sunscreens and skin cancer. J Clin Invest 2007; 117: 3658-3660.
49. Reichrath J, et al,. Analysis of 1,25-Dihydroxyvitamin D3 Receptors (VDR. in Basal Cell Carcinomas. Am J Pathol 1999; 155: 583-589.
50. Campbell FC, et al,. The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol 2010; 79: 1-9.
51. Oda Y, et al,. Differential role of two VDR coactivators, DRIP205 and SRC-3, in keratinocyte proliferation and differentiation. J Steroid Biochem Mol Biol 2007; 103: 776-780.
52. Bikle DD, et al,. Mice lacking 25OHD 1[alpha]-hydroxylase demonstrate decreased epidermal differentiation and barrier function. J Steroid Biochem Mol Biol 2004; 89-90: 347-353.
53. Nemanic MK, et al,. Vitamin D3 production by cultured human keratinocytes and fibroblasts. Biochem Biophys Res Commun 1983; 115: 444-450.
54. Koivisto L, et al,. HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3[alpha]. Exp Cell Res 2006; 312: 2791-2805.
55. Ramirez AM, et al,. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor [beta]1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol 2010; 118: 142-150.
56. Xu K, et al,. The role of fibroblast Tiam1 in tumor cell invasion and metastasis. Oncogene 2010; 29: 6533-6542.
57. Lou Y-R, et al,. 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J 2004; 18: 332-334.
58. Nguyen TH,. Mechanisms of metastasis. Clin Dermatol 2004; 22: 209-216.
59. Puccinelli TJ, et al,. Regulation of keratinocyte signaling and function via changes in epidermal growth factor presentation. Acta Biomater 2010; 6: 3415-3425.
60. Vantieghem K, et al,. Dermal fibroblasts pretreated with a sterol [Delta]7-reductase inhibitor produce 25-hydroxyvitamin D3 upon UVB irradiation. J Photochem Photobiol B 2006; 85: 72-78.
61. Tang JY, et al,. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol 2007; 224: 257-264.
62. Bikle DD,. Vitamin D: an ancient hormone. Exp Dermatol 2011; 1: 7-13.
63. Cross HS,. Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells: modification of expression by epigenetic mechanisms and dietary substances. Nutr Rev 2007; 65: S108-S112.
64. Bremnes RM,. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011; 6: 209-217.
65. Micke P, Tman A,. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45: S163-S175.
66. Dusso AS, et al,. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
67. Balasubramanian S, Eckert RL,. Keratinocyte proliferation, differentiation, and apoptosis-differential mechanisms of regulation by curcumin, EGCG and apigenin. Toxicol Appl Pharmacol 2007; 224: 214-219.
68. Tuohimaa P,. Vitamin D and aging. J Steroid Biochem Mol Biol 2009; 114: 78-84.
69. Nagpal S, et al,. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
70. Zinser GM, et al,. Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 2002; 23: 2103-2109.
71. Lou Y-R, et al,. 25-hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J 2003; 18: 332-334.
72. Lips P,. Vitamin D physiology. Prog Biophys Mol Biol 2006; 92: 4-8.
73. Nicol CJ, et al,. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004; 25: 1747-1755.
74. Valrance ME, et al,. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo. Endocrinology 2007; 148: 4887-4894.
75. Nykjaer A, et al,. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515.
76. Christakos S,. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003; 88: 695-705.
77. Zehnder D, et al,. Extrarenal expression of 25-hydroxyvitaminD3-1a- hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-894.
78. Chan AT, et al,. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2004; 2: 704-712.
79. Chen W, et al,. Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer 2007; 97: 23-28.
80. Clairmont A, et al,. Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear vitamin D receptor. Carcinogenesis 1996; 17: 1389-1391.
81. Ng K, et al,. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. Br J Cancer 2009; 101: 916-923.
82. Porojnicu A, et al,. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: a possible role of sun-induced Vitamin D. J Steroid Biochem Mol Biol 2007; 103: 675-678.
83. Porojnicu AC, et al,. Seasonal and geographical variations in lung cancer prognosis in Norway: does vitamin D from the sun play a role? Lung Cancer 2007; 55: 263-270.
84. Mancuso M, et al,. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis 2009; 30: 721.
85. Correa P, et al,. Increased 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase and reduced 25-Hydroxyvitamin D3 24-Hydroxylase expression in parathyroid tumors: new prospects for treatment of hyperparathyroidism with vitamin D. J Clin Endocrinol Metab 2002; 87: 5826-5829.
86. Tang JY, et al,. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 2010; 21: 387-391.
87. Holick MF,. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am 2010; 39: 381-400.
88. Mocellin S, Nitti D,. Vitamin D receptor polymorphisms and the risk of cutaneous melanoma. Cancer 2008; 113: 2398-2407.
89. Reichrath J,. Dermatologic management, sun avoidance and vitamin D status in organ transplant recipients (OTR). J Photochem Photobiol B 2010; 101: 150-159.
90. Uitterlinden AG, et al,. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-156.
91. Midorikawa K, et al,. Expression of vitamin D receptor in cultured human keratinocytes and fibroblasts is not altered by corticosteroids. J Dermatol Sci 1999; 21: 8-12.
92. Zwaan SD,. The Genetics of Basal Cell Carcinoma of the Skin. Sydney: University of Sydney, 2007.
93. Keisala T, et al,. Premature aging in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 2009; 115: 91-97.
94. Kerr Whitfield G, et al,. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001; 177: 145-159.
95. Savkur RS, et al,. Coactivation of the human vitamin D receptor by the peroxisome proliferator-activated receptor gamma coactivator-1 alpha. Mol Pharmacol 2005; 68: 511-517.